EADV 2022 Highlights Podcast

In this episode (17:07 min), Medicom’s correspondent covers 6 presentations from the European Academy of Dermatiology and Venereology (EADV) in Milan, Italy from 7-10 September 2022.

1. Activation of the A3 adenosine receptor: a new mode of action to treat psoriasis?
   Findings from the COMFORT phase 3 trial reported that piclidenoson reached its primary endpoint
   with a statistical difference over placebo while showing a very good safety profile. However, the A3
   adenosine receptor agonist did not outperform the active comparator apremilast.


2. JAK3/TEC blockade leads to long-term improvement in alopecia areata
   The first long-term results of the JAK3/TEC kinase inhibitor ritlecitinib in alopecia areata (AA) were
   presented at EADV 2022. Ritlecitinib showed sustained efficacy over a treatment period up to month
   36 with no new safety signals. Patient-reported outcomes improved already after a treatment phase
   of 3 months.


3. Kappa-opioid receptor agonist shows remarkable efficacy in nostalgia paresthetica
   According to the results of the phase 2 KOMFORT trial, difelikefalin leads to rapid decrease in pruritus
   in patients with notalgia paresthetica, a very common, underdiagnosed condition with a high medical
   need due to the lack of treatment possibilities. Significant changes from placebo in pruritus were
   already seen on day 1.


4. IL4/IL13 blockade shows remarkable efficacy in prurigo nodularis
   In the phase 2 LIBERTY-PN PRIME trial presented as a late breaker, patients with prurigo nodularis
   treated with dupilumab showed a remarkable itch improvement from baseline to week 24. This is
   already the second phase 2 trial showing that dupilumab reduced both pruritus and the number of
   prurigo nodularis lesions.


5. Nalbuphine: another candidate for an approved treatment in prurigo nodularis?
   The results of the PRISM trial on prurigo nodularis (PN) were positive regarding all endpoints:
   Significantly more patients on nalbuphine achieved at least a 4-point decrease on the worst itch (WI-)
   numeric rating scale (NRS), quality-of-life (QoL) rose, and skin lesions improved.


6.  Novel JAK inhibitor deuruxolitinib effective in alopecia areata
   The investigative JAK inhibitor deuruxolitinib showed to be highly effective in severe alopecia areata
   (AA) in the phase 3 THRIVE-AA1 trial. The positive results were mirrored in a high percentage of
   satisfied or very satisfied patients. The JAK inhibitor also led to the re-growth of eyebrows.

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers



Posted on 27 September 20222 October 2024